Business & Industry

novartis-logo

Novartis announces 300 million antimalarial treatments supplied without profit

Novartis has announced that the company has reached a delivery milestone of supplying 300 million pediatric antimalarial treatments without profit since 2009, helping to reduce the disease burden for children in more than 30 malaria-endemic countries. Coartem Dispersible is the first artemisinin-combination therapy (ACT) developed by Novartis in collaboration with Medicines for Malaria Venture (MMV)

novartis-logo

Novartis announces 300 million antimalarial treatments supplied without profit

Novartis has announced that the company has reached a delivery milestone of supplying 300 million pediatric antimalarial treatments without profit since 2009, helping to reduce the disease burden for children in more than 30 malaria-endemic countries. Coartem Dispersible is the first artemisinin-combination therapy (ACT) developed by Novartis in collaboration with Medicines for Malaria Venture (MMV)

IFC extends facility to Nigeria pharmacy chain, HealthPlus

The International Finance Corporation (IFC), a member of the World Bank Group, has announced an agreement with HealthPlus Limited and CasaBella International Limited to provide a $5 million loan facility that will help the two companies expand pharmaceutical and personal care services in Nigeria.

NovaBay-Pharma-Logo-101912

NovaBay signs distribution agreement with the Biopharm Group

NovaBay Pharmaceuticals, a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, has signed an exclusive distribution agreement for NovaBay’s NeutroPhase Skin and Wound Cleanser with the Biopharm Group, a leading pharmaceutical company in the Middle East, headquartered in Cairo, Egypt. Under the terms of the agreement, Biopharm will market NeutroPhase

Deals

The Medicines Patent Pool Signs First Sub-licences for Hepatitis C Medicine Daclatasvir

Four companies to help speed access to curative direct-acting antiviral in 112 low- and middle-income countries The Medicines Patent Pool (MPP) has announced its first round of sub-licences for the generic production of Bristol-Myers Squibb’s daclatasvir, a direct-acting antiviral that is proven to help cure multiple genotypes of the hepatitis C virus. Generic companies Cipla,

Policy & Regulatory Affairs

The Medicines Patent Pool Signs First Sub-licences for Hepatitis C Medicine Daclatasvir

Four companies to help speed access to curative direct-acting antiviral in 112 low- and middle-income countries The Medicines Patent Pool (MPP) has announced its first round of sub-licences for the generic production of Bristol-Myers Squibb’s daclatasvir, a direct-acting antiviral that is proven to help cure multiple genotypes of the hepatitis C virus. Generic companies Cipla,

The Medicines Patent Pool Signs First Sub-licences for Hepatitis C Medicine Daclatasvir

Four companies to help speed access to curative direct-acting antiviral in 112 low- and middle-income countries The Medicines Patent Pool (MPP) has announced its first round of sub-licences for the generic production of Bristol-Myers Squibb’s daclatasvir, a direct-acting antiviral that is proven to help cure multiple genotypes of the hepatitis C virus. Generic companies Cipla,

Pharma Projects

JohnsonJohnson_Logo

Johnson & Johnson unveils R300m plant makeover, targets growth in Nigeria

Johnson & Johnson have unveiled their modernised manufacturing plant in Cape Town, South Africa yesterday. The plant, located in Retret, underwent a R300 million upgrade to and is responsible for supplying more than 28 markets within Sub Sahara Africa. Pharmaceutical exports from South Africa amounted to R1.6 billion in 2013, of which more than half went

Plans set for new ARV production plant in Ghana

Oxford International Biomedical Ventures (OIBV), the ‘commercial arm’ of  United Kingdom-based charitable organisation Oxford International Biomedical Centre (OIBC) and the Government of Ghana (GoG) led by the Ministry of Environment, Science and Technology (MEST), are set to jointly establish a plant to manufacture anti-retroviral drugs and drugs for Priority Endemic Diseases in Ghana, OIBC said in a

People

Neimeth appoints acting MD/CEO

Neimeth International Pharmaceuticals Plc has announced the appointment of (Mrs.) Ebere Igboko Ekpunobi  as the acting Managing Director/CEO of the Company effective 23 November 2015 following the retirement of Mr. Emmanuel Princewill Ekunno. Dr. (Mrs.) Ebere Igboko Ekpunobi obtained a Bachelor of Pharmacy degree from the University of Nigeria Nsukka (1985) and a Master of

Press Releases

International

arc

What is needed to accelerate access to quality medicines & vaccines in Africa?

GUEST ARTICLE By Paul Dearden, Abbvie;  Dakshina Reddy, Novartis Members of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) African Regulatory Network   In a globalized world, the regulatory landscape is changing every day to address, in tandem, old and new challenges. With regulatory systems increasingly under pressure globally, what will be the most

Top